In contrast, TNFα release was significantly less affected by JAK1 inhibition as compared to tofacitinib and ruxolitinib, possibly indicating that JAK1 inhibitors may not be as efficacious in patients with diseases such as rheumatoid arthritis and psoriasis, where anti‐TNFα treatment has proved successful. The gene discussed is JAK1; the disease is psoriasis.